SCHEMBL5135487

SCHEMBL5135487

CCCCN(Cc1ccc(O)cc1)Cc1c(-c2ccccc2)nc(-c2ccccc2OC)n1CCCC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 2/20 0.38
C5AR1 P21730 1/20 0.37
BCL2L2 Q92843 1/20 0.36
HTR1A P08908 1/20 0.36
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
HDAC1 Q13547 1/20 0.35
GAA P10253 2/20 0.35
MGAM O43451 1/20 0.35
SI P14410 1/20 0.35
MGAM2 Q2M2H8 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CRHR1 P34998 2/20 0.35
ATP4A P20648 1/20 0.35
ATP4B P51164 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
AGTR1 P30556 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5138077 0.93 C5AR1 (0.39) BCHEC5AR1BCL2L2HTR1AHTR2C
SCHEMBL5136942 0.88 C5AR1 (0.46) C5AR1HDAC1CRHR1ATP4AATP4B
SCHEMBL5135868 0.88 CA2 (0.38) C5AR1ALDH1A1
SCHEMBL5136452 0.87 HDAC1 (0.36) BCHEC5AR1BCL2L2HTR1AHTR2C
SCHEMBL5134726 0.87 ATP4A (0.41) BCHEC5AR1GAAATP4AATP4B
SCHEMBL14099515 0.86 BCL2L2 (0.39) C5AR1BCL2L2HTR1AHTR2CHTR2B
SCHEMBL5136254 0.85 C5AR1 (0.39) BCHEC5AR1BCL2L2HTR1AHTR2C
SCHEMBL5135240 0.85 C5AR1 (0.42) BCHEC5AR1CRHR1ATP4AATP4B
SCHEMBL4766754 0.84 C5AR1 (0.57) C5AR1HTR1AHTR2CHTR2BMEN1
SCHEMBL5136565 0.84 BCL2L2 (0.36) BCHEC5AR1BCL2L2HTR1AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed